Document Detail


Studio del possibile ruolo predittivo del polimorfismo -174G>C del promotore dell'IL-6 nei confronti della risposta al rituximab in corso di artrite reumatoide.
MedLine Citation:
PMID:  21253618     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
OBJECTIVE: Identification of genetic biomarkers of response to biologics in rheumatoid arthritis (RA) is a relevant issue. The -174G>C interleukin-6 (IL-6) promoter polymorphism was investigated in RA patients treated with rituximab (RTX), being IL-6 a key cytokine for B cell survival and proliferation, thus possibly implicated in rituximab efficacy. METHODS: The study was conducted in a real-life retrospective cohort of 142 unselected RA patients (120F/22M) treated with RTX and referred to 7 rheumatologic centres in the north of Italy. One hundred and thirteen (79.6%) patients were rheumatoid factor (RF)-positive and 112 (78.9%) were anti-CCP antibodies positive. The response to therapy was evaluated at the end of the sixth month after the first RTX infusion, by using both the EULAR criteria (DAS28) and the ACR criteria. The IL-6 -174G>C promoter polymorphism was analyzed by RFLP following previously reported methods. RESULTS: Lack of response to RTX at month +6 by EULAR criteria was more prevalent in RA patients with the IL-6 -174 CC genotypes (9/21, 42.8%), than in the GC/GG patients (23/121, 19.0%) (OR 3.196, 95% CI=1.204-8.485; p=0.0234). Similar results were found when evaluating the response by ACR criteria. No differences were found in RA duration, baseline DAS28, baseline HAQ, RF status, anti-CCP status according to the different IL-6 -174 genotypes. CONCLUSION: IL-6 promoter genotyping may be useful to better plan treatment with RTX in RA. Larger replication studies are in course to confirm these preliminary results.
Authors:
M Fabris; L Quartuccio; S Lombardi; M Benucci; M Manfredi; M Saracco; F Atzeni; P Morassi; M A Cimmino; E Pontarini; C Fabro; R Pellerito; P Sarzi-Puttini; M Cutolo; A Carletto; L M Bambara; F Fischetti; F Curcio; E Tonutti; S De Vita
Related Documents :
21858258 - Visual analogue scale assessment of nasal obstruction might define patients candidates ...
1191888 - Statistical analysis of individually matched case-control studies in epidemiology: fact...
10461428 - The imbalance between coagulation and fibrinolysis is related to the severity of the il...
3107318 - Protein c and antithrombin iii in polytransfused thalassemic patients.
20565688 - Physiology of diffuse esophageal spasm (des)--when normal swallows are not normal.
9055008 - Varicella pneumonia in adults--clinical spectrum.
Publication Detail:
Type:  JOURNAL ARTICLE    
Journal Detail:
Title:  Reumatismo     Volume:  62     ISSN:  0048-7449     ISO Abbreviation:  -     Publication Date:  2010  
Date Detail:
Created Date:  2011-1-21     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0401302     Medline TA:  Reumatismo     Country:  -    
Other Details:
Languages:  ENG     Pagination:  253-258     Citation Subset:  -    
Affiliation:
Clinical Pathology and Clinic of Rheumatology, Azienda Ospedaliero-Universitaria of Udine, Udine, Italy. fabris.martina@aoud.sanita.fvg.it.
Vernacular Title:
Study on the possible role of the -174G>C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  How much does an antiinflammatory treatment cost?
Next Document:  BAFF/APRIL pathway in Sjögren syndrome and systemic lupus erythematosus: relationship with chronic i...